# PDUFA dates December 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-12

> 162 FDA catalysts are dated in December 2025, including 23 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in December 2025?

PDUFA dates in December 2025: BRISTOL MYERS SQUIBB CO (BMY) on December 5, 2025; PYRUKYND® (pyrukynd, AGIO) on December 7, 2025; GSK plc (GSK) on December 11, 2025; BIOCRYST PHARMACEUTICALS INC (BCRX) on December 12, 2025; ORLADEYO® (berotralstat, BCRX) on December 12, 2025; CARDAMYST (etripamil, MIST) on December 13, 2025; and 17 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-12)

Source: Press release filed with the SEC (EX-99), accession 0000014272-25-000147, https://www.sec.gov/Archives/edgar/data/14272/000001427225000147/a2025q3ex991.htm (retrieved 2026-11-12). Last confirmed 2025-10-30. Cite: https://sec-api.dev/fda-calendar/2025-12#answer

## PDUFA dates in December 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| December 5, 2025 | BRISTOL MYERS SQUIBB CO | BMY |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000147/a2025q3ex991.htm) |
| December 7, 2025 | AGIOS PHARMACEUTICALS, INC. | AGIO | PYRUKYND® (pyrukynd) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm) |
| December 11, 2025 | GSK plc | GSK |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425012307/a1902f-gskoriginaledgar.htm) |
| December 12, 2025 | BIOCRYST PHARMACEUTICALS INC | BCRX |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm) |
| December 12, 2025 | BIOCRYST PHARMACEUTICALS INC | BCRX | ORLADEYO® (berotralstat) | HAE aged 2 to 11 | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/exh_991.htm) |
| December 13, 2025 | Milestone Pharmaceuticals Inc. | MIST | CARDAMYST (etripamil) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm) |
| December 14, 2025 | AMGEN INC | AMGN |  | generalized myasthenia gravis | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm) |
| December 15, 2025 | Innoviva, Inc. | INVA | NUZOLVENCE® (zoliflodacin) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1080014/000119312525267040/inva-20250930.htm) |
| December 15, 2025 | Aldeyra Therapeutics, Inc. | ALDX | reproxalap | signs and symptoms of dry eye disease | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-20251215.htm) |
| December 16, 2025 | Aldeyra Therapeutics, Inc. | ALDX | reproxalap | signs and symptoms of dry eye disease | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm) |
| December 18, 2025 | AMGEN INC | AMGN | IMDELLTRA® (tarlatamab) | relapsed ES-SCLC | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm) |
| December 20, 2025 | RHYTHM PHARMACEUTICALS, INC. | RYTM | IMCIVREE® (setmelanotide) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm) |
| December 26, 2025 | OMEROS CORP | OMER | YARTEMLEA® (narsoplimab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm) |
| December 26, 2025 | CYTOKINETICS INC | CYTK | MYQORZO® (aficamten) | with obstructive hypertrophic cardiomyopathy | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm) |
| December 26, 2025 | OMEROS CORP | OMER |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1285819/000110465925070554/tm2516030d4_8k.htm) |
| December 28, 2025 | Sanofi | SNY | tolebrutinib |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525332163/d65502dex991.htm) |
| December 30, 2025 | Vanda Pharmaceuticals Inc. | VNDA | NEREUSTM (tradipitant) | motion sickness | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025055393/vnda8-k1242025exhibit991.htm) |
| December 30, 2025 | NRX Pharmaceuticals, Inc. | NRXP | KETAFREE (ketamine) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm) |
| December 30, 2025 | CORCEPT THERAPEUTICS INC | CORT | corcept |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/d914293dex991.htm) |
| December 30, 2025 | CORCEPT THERAPEUTICS INC | CORT | Lifyorli™ (relacorilant) | hypercortisolism | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm) |
| December 31, 2025 | Outlook Therapeutics, Inc. | OTLK |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm) |
| December 31, 2025 | NRX Pharmaceuticals, Inc. | NRXP | KETAFREE (ketamine) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/ex_792256.htm) |
| December 31, 2025 | Outlook Therapeutics, Inc. | OTLK | MVASI® (bevacizumab) | wet AMD | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm) |

## All catalysts in December 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 1, 2025 | [PAVBLU® (aflibercept) interim data readout](https://sec-api.dev/pdufa/aflibercept) | FDMT |  | completed, positive | "Announced positive long-term interim results from the AEROW Phase 1/2 clinical trial (data cut-off: December 1, 2025)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm)) |
| December 1, 2025 | [Pamiparib capsule primary completion](https://sec-api.dev/pdufa/pamiparib) | ONC | Ovarian Cancer | completed | "NCT03519230 (Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03519230)) |
| December 1, 2025 | [Juvmo (tavapadon) primary completion](https://sec-api.dev/pdufa/tavapadon) | ABBV | Parkinson Disease | completed | "NCT04760769 (Open-label Trial in Parkinson's Disease (PD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04760769)) |
| December 1, 2025 | [Ropidoxuridine primary completion](https://sec-api.dev/pdufa/ropidoxuridine) | SHPH | Glioblastoma, IDH-wildtype | withdrawn | "NCT06359379 (Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor Shuttle Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06359379)) |
| December 2, 2025 | [PEDMARK (pedmark) trial start](https://sec-api.dev/pdufa/pedmark) | FENC |  | completed | "2025 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_ex99-1.htm)) |
| December 2, 2025 | [Cisplatin topline data readout](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed, positive | "On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_8k.htm)) |
| December 2, 2025 | [PEDMARK (pedmark) topline data readout](https://sec-api.dev/pdufa/pedmark) | FENC |  | completed, positive | "2025 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_ex99-1.htm)) |
| December 2, 2025 | [Cisplatin trial start](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed | "On December 2, 2025, Fennec Pharmaceuticals Inc. issued a news release and announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_8k.htm)) |
| December 2, 2025 | [Jaypirca (pirtobrutinib) label expansion decision](https://sec-api.dev/pdufa/pirtobrutinib) | LLY |  | completed, approved | "NDA216059 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251202, review_priority STANDARD; sponsor_name LOXO ONCOL; product JAYPIRCA (PIRTOBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216059%22)) |
| December 3, 2025 | [Deramiocel topline data readout](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, positive | "SAN DIEGO, Dec. 3, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465925117947/capr-20251203xex99d1.htm)) |
| December 3, 2025 | [Varegacestat primary completion](https://sec-api.dev/pdufa/varegacestat) | IMNM | Desmoid; Desmoid Tumor | completed | "NCT04871282 (A Study of AL102 in Patients With Progressing Desmoid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-12-03 (ACTUAL); Lead Sponsor Immunome, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04871282)) |
| December 3, 2025 | [AZD6234 primary completion](https://sec-api.dev/pdufa/azd6234) | AZN | Obesity or Overweight | completed | "NCT06595238 (A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-03 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06595238)) |
| December 4, 2025 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "MapLight Therapeutics Reports Third Quarter Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm)) |
| December 4, 2025 | [TARA-002 interim data readout](https://sec-api.dev/pdufa/tara-002) | TARA |  | completed, positive | "December 4, 2025, we presented updated interim data from our ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at a poster session at the 2025 Annual Meeting of the Society of Urologic Oncology (SUO) Conference, reporting positive results that continue to support TARA-002's potential as a mainstay in the NMIBC treatment landscape and demonstrating meaningful and durable activity in BCG-Na&iuml;ve NMIBC patients." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025118744/ea0268632-424b5_protara.htm)) |
| December 4, 2025 | [BGE-102 interim data readout](https://sec-api.dev/pdufa/bge-102) | BIOA |  | completed, positive | "On December 4, 2025, the Company announced positive interim data from its ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) clinical trial evaluating BGE-102 a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for treatment of patients with cardiovascular risk factors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312525307541/bioa-20251204.htm)) |
| December 4, 2025 | [Reyvow (lasmiditan succinate) primary completion](https://sec-api.dev/pdufa/lasmiditan) | LLY | Migraine | withdrawn | "NCT04396574 (A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04396574)) |
| December 4, 2025 | [Rsvt vaccine primary completion](https://sec-api.dev/pdufa/rsvt-vaccine) | SNY | RSV Immunisation | withdrawn | "NCT06252285 (Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06252285)) |
| December 4, 2025 | [Arq-151 cream 0.05% primary completion](https://sec-api.dev/pdufa/arq-151-cream-0-05) | ARQT | Atopic Dermatitis (Eczema) | completed | "NCT06998056 (Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Arcutis Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06998056)) |
| December 5, 2025 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act goal date of December 5, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000147/a2025q3ex991.htm)) |
| December 5, 2025 | [Century Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | scheduled | "Initial clinical data from CARAMEL is expected to be presented by the trial investigators at the 14th Annual BMT & Cell Therapy Workshop on December 5, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/tm2530897d1_ex99-1.htm)) |
| December 5, 2025 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Facial Volume Deficit | completed | "NCT05818709 (A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-05 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05818709)) |
| December 6, 2025 | [Bezuclastinib topline data readout](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed, positive | "On December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. (the "Company") presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis ("NonAdvSM") and announced positive top-line results from its APEX clinical trial of bezuclastinib in patients with advanced systemic mastocytosis ("AdvSM"), respectively." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1622229/000119312525311217/d81277d8k.htm)) |
| December 6, 2025 | [CRISPR Therapeutics AG interim data readout](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | scheduled | "Initial data from these studies will be presented at the American Society of Hematology (ASH) annual meeting on December 6th, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/crsp-ex99_1.htm)) |
| December 7, 2025 | [TLX591 trial start](https://sec-api.dev/pdufa/tlx591) | TLX | metastatic castration resistant prostate cancer | completed | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000073/prostactpr.htm)) |
| December 7, 2025 | [PYRUKYND® (pyrukynd) PDUFA date](https://sec-api.dev/pdufa/pyrukynd) | AGIO |  | scheduled | "•PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922225000114/agio-103125xfyxex991earnin.htm)) |
| December 8, 2025 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed, positive | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_ex99-1.htm)) |
| December 8, 2025 | [Rostudirsen topline data readout](https://sec-api.dev/pdufa/rostudirsen) | DYN | Duchenne muscular dystrophy | completed, positive | "WALTHAM, Mass., December 8, 2025 - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced positive topline results from the Registrational Expansion Cohort (REC) of its Phase 1/2 DELIVER trial evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312525310516/d16518dex991.htm)) |
| December 8, 2025 | [WVE-007 interim data readout](https://sec-api.dev/pdufa/wve-007) | WVE | obesity | completed, positive | "CAMBRIDGE, Mass., December 8, 2025 - Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave's proprietary SpiNA design, for the treatment of obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312525310595/d20484dex991.htm)) |
| December 8, 2025 | [LY3871801 primary completion](https://sec-api.dev/pdufa/ly3871801) | LLY | Rheumatoid Arthritis | completed | "NCT05848258 (An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05848258)) |
| December 8, 2025 | [Soliris (eculizumab) topline data readout](https://sec-api.dev/pdufa/eculizumab) | AZN | Atypical Hemolytic Uremic | completed | "NCT05876351 (Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2025-12-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05876351?tab=results)) |
| December 8, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Obesity | completed | "NCT06131437 (A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06131437)) |
| December 9, 2025 | [WELTRUZATM (olanzapine) NDA/BLA submission](https://sec-api.dev/pdufa/olanzapine) | TEVA |  | completed | "On December 9, 2025, Teva submitted a New Drug Application ("NDA") to the FDA for olanzapine LAI (TEV-'749), based on the results from the Phase 3 trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| December 9, 2025 | [Pumitamig interim data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | locally advanced/metastatic triple-negative breast cancer | completed, negative | "MAINZ, Germany, and PRINCETON, USA, December 9, 2025 - BioNTech SE (Nasdaq: BNTX, "BioNTech") and Bristol Myers Squibb Company (NYSE: BMY, "BMS") today announced the first interim data from a global randomized Phase 2 trial (NCT06449222) evaluating pumitamig (BNT327/BMS986545), an investigational bispecific antibody targeting PD-L1 and VEGF-A, plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer ("TNBC") irrespective of PD-L1 expression levels." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000071/a991251209_bntxbmsxprxpumi.htm)) |
| December 9, 2025 | [PT00114 topline data readout](https://sec-api.dev/pdufa/pt00114) | PTIX |  | completed, positive | "On December 9, 2025 we announced positive topline safety results from its Phase 1 Multiple Dose (MD) study of PT00114." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1022899/000149315226050425/form10-q.htm)) |
| December 9, 2025 | [Recarbrio (cilastatin sodium; imipenem; relebactam) label expansion decision](https://sec-api.dev/pdufa/cilastatin-imipenem-relebactam) | MRK |  | completed, approved | "NDA212819 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20251209, review_priority STANDARD; sponsor_name MSD MERCK CO; product RECARBRIO (CILASTATIN SODIUM; IMIPENEM; RELEBACTAM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212819%22)) |
| December 9, 2025 | [TAK-101 primary completion](https://sec-api.dev/pdufa/tak-101) | TAK | Celiac Disease | completed | "NCT04530123 (Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-09 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530123)) |
| December 9, 2025 | [Tevimbra (tislelizumab-jsgr) label expansion decision](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761232 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251209, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22)) |
| December 10, 2025 | [ARD-101 trial start](https://sec-api.dev/pdufa/ard-101) | AARD | hyperphagia in individuals with Prader-Willi syndrome | completed | "On December 10, 2025, Aardvark Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in Australia in the Company's Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1774857/000119312525314364/ck0001774857-20251210.htm)) |
| December 10, 2025 | [Arazlo® (tazarotene) topline data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed, positive | "LA JOLLA, CA, December 10, 2025 -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced positive topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000167/ex991_pressreleasetoplined.htm)) |
| December 10, 2025 | [NovaBridge Biosciences interim data readout](https://sec-api.dev/companies/nbp/catalysts) | NBP |  | scheduled | "The interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be presented in a poster session at ESMO-IO on December 10, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525307454/nbp-ex99_1.htm)) |
| December 10, 2025 | [Galcanezumab primary completion](https://sec-api.dev/pdufa/galcanezumab) | LLY | Chronic Migraine | completed | "NCT04616326 (A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-10 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04616326)) |
| December 11, 2025 | [IMCIVREE® (setmelanotide) interim data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed, positive | "On December 11, 2025, we announced positive interim results from our exploratory Phase 2 trial of setmelanotide in patients with PWS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649904/000162828026030549/rytm-20260331.htm)) |
| December 11, 2025 | [Evommune, Inc. earnings report](https://sec-api.dev/companies/evmn/catalysts) | EVMN |  | completed | "Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/evmn-ex99_1.htm)) |
| December 11, 2025 | [RM-718 trial start](https://sec-api.dev/pdufa/rm-718) | RYTM |  | completed | "•On December 11, 2025, the Company announced that it has initiated a Part D arm in the Phase 1/2 trial of MC4R agonist RM-718 that will enroll up to 20 patients with PWS; and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026011987/rytm4q2025earningspr_v1.htm)) |
| December 11, 2025 | [THIO-104 trial start](https://sec-api.dev/pdufa/thio-104) | MAIA |  | completed | "Press Release dated December 11, 2025 (First Patient Dosed in THIO-104 Phase 3 Pivotal Trial)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1878313/000149315225027244/form8-k.htm)) |
| December 11, 2025 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390025120691/ea026912701ex99-1_rafael.htm)) |
| December 11, 2025 | [ORLADEYO® (berotralstat) FDA approval](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to <12 years | completed, approved | "NDA219776 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20251211, review_priority PRIORITY; sponsor_name BIOCRYST; product ORLADEYO (BEROTRALSTAT DIHYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219776%22)) |
| December 11, 2025 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "Act action date of 11 December 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425012307/a1902f-gskoriginaledgar.htm)) |
| December 11, 2025 | [Blujepa (gepotidacin mesylate) label expansion decision](https://sec-api.dev/pdufa/gepotidacin) | GSK |  | completed, approved | "NDA218230 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251211, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BLUJEPA (GEPOTIDACIN MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218230%22)) |
| December 11, 2025 | [Fluoride free toothpaste in a chalk base primary completion](https://sec-api.dev/pdufa/fluoride-free-toothpaste-in-a-chalk-base) | CL | Demineralization; Remineralization; Dental Cavity | completed | "NCT07134231 (Clinical Study to Evaluate the Anti-cavity Efficacy of Three Dentifrices: An In Situ Model): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-11 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07134231)) |
| December 12, 2025 | [BIOCRYST PHARMACEUTICALS INC PDUFA date](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | scheduled | "The new PDUFA target action date for our NDA is December 12, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm)) |
| December 12, 2025 | [Raxibacumab label expansion decision](https://sec-api.dev/pdufa/raxibacumab) | EBS |  | completed, approved | "GAITHERSBURG, Md., December 12, 2025 (GLOBE NEWSWIRE) - Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/a12122025raxi.htm)) |
| December 12, 2025 | [CARDAMYST (etripamil) FDA approval](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, approved | "On December 12, 2025, we announced the FDA approved our first commercial product, CARDAMYST® (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1408443/000110465926126504/mist-20260930x10q.htm)) |
| December 12, 2025 | [Akeega (abiraterone acetate; niraparib tosylate) label expansion decision](https://sec-api.dev/pdufa/abiraterone-niraparib) | JNJ |  | completed, approved | "NDA216793 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251212, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product AKEEGA (ABIRATERONE ACETATE; NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216793%22)) |
| December 12, 2025 | [ORLADEYO® (berotralstat) PDUFA date](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to 11 | completed, approved | "The Prescription Drug User Fee Act goal date for the company's new drug application for ORLADEYO granules in children with HAE aged 2 to <12 is December 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/exh_991.htm)) |
| December 12, 2025 | [Edesa Biotech, Inc. earnings report](https://sec-api.dev/companies/edsa/catalysts) | EDSA |  | completed | "TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm)) |
| December 13, 2025 | [CARDAMYST (etripamil) PDUFA date](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed, approved | "FDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm)) |
| December 14, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN | generalized myasthenia gravis | scheduled | "•U.S. Food and Drug Administration (FDA) review of the MINT Phase 3 data in patients with generalized myasthenia gravis is ongoing, with a PDUFA date of December 14, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| December 15, 2025 | [Varegacestat topline data readout](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | completed, positive | "On December 15, 2025, Immunome, Inc. (the Company, we or our) announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961d8k.htm)) |
| December 15, 2025 | [NUZOLVENCE® (zoliflodacin) PDUFA date](https://sec-api.dev/pdufa/zoliflodacin) | INVA |  | scheduled | "Zoliflodacin is currently under Priority Review by the FDA, with a Prescription Drug User Fee Act ("PDUFA") target action date of December 15, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1080014/000119312525267040/inva-20250930.htm)) |
| December 15, 2025 | [Mivocabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/mivocabtagene-autoleucel) | KYTX | autoimmune diseases, today | completed, positive | "EMERYVILLE, Calif., December 15, 2025 - Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel ('miv-cel', formerly KYV-101), a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome (SPS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312525318377/d285116dex991.htm)) |
| December 15, 2025 | [ZYCUBO (CUTX-101) NDA/BLA acceptance](https://sec-api.dev/pdufa/cutx-101) | FBIO | Menkes disease in pediatric patients | completed | "Miami, FL - December 15, 2025 - Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has accepted the resubmission of the New Drug Application ("NDA") for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465925120893/fbio-20251215xex99.htm)) |
| December 15, 2025 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - December 15, 2025 - Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000162828025057020/csbr8-k10312025ex991xq226.htm)) |
| December 15, 2025 | [Rapamycin topline data readout](https://sec-api.dev/pdufa/rapamycin) | PVLA |  | completed, positive | "2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced positive topline results from the Company's Phase 2 TOIVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000110465925120789/tm2533458d1_ex99-2.htm)) |
| December 15, 2025 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | delayed | "On December 15, 2025, Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") issued a press release (the "Press Release") to announce that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act ("PDUFA") date for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-20251215.htm)) |
| December 15, 2025 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Thyroid Eye Disease | withdrawn | "NCT06307613 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307613)) |
| December 15, 2025 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Thyroid Eye Disease | withdrawn | "NCT06307626 (A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307626)) |
| December 15, 2025 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity | completed | "NCT06373146 (A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06373146)) |
| December 15, 2025 | [Rmenb+omv nz vaccine primary completion](https://sec-api.dev/pdufa/rmenb-omv-nz-vaccine) | GSK | Meningitis | completed | "NCT06995430 (A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-11-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06995430)) |
| December 16, 2025 | [VIASKIN (viaskin) topline data readout](https://sec-api.dev/pdufa/viaskin) | DBVT |  | completed, positive | "On December 16, 2025, the Company announced positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/dbvt-20251231.htm)) |
| December 16, 2025 | [MRT-2359 interim data readout](https://sec-api.dev/pdufa/mrt-2359) | GLUE |  | completed, positive | "On December 16, 2025, the Company announced positive interim data from its ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic CRPC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1826457/000119312525319981/glue-20251216.htm)) |
| December 16, 2025 | [Exdensur (depemokimab-ulaa) FDA approval](https://sec-api.dev/pdufa/depemokimab-ulaa) | GSK |  | completed, approved | "Exdensur \| depemokimab-ulaa \| 12/16/2025 \| To treat severe asthma characterized by an eosinophilic phenotype as an Komziftiadd-on maintenance therapyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| December 16, 2025 | [Exdensur (depemokimab-ulaa) complete response letter (CRL)](https://sec-api.dev/pdufa/depemokimab-ulaa) | GSK |  | completed, complete response letter | "We have completed the review of BLA 761458/Original 2 and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761458_20251216.pdf%22)) |
| December 16, 2025 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | scheduled | "On July 17, 2025, Aldeyra announced that the FDA accepted the reproxalap NDA for review and assigned a PDUFA date of December 16, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| December 16, 2025 | [PFIZER INC primary completion](https://sec-api.dev/companies/pfe/catalysts) | PFE | Esophagitis | withdrawn | "NCT04821310 (Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04821310)) |
| December 16, 2025 | [Verekitug (upb-101) primary completion](https://sec-api.dev/pdufa/verekitug-upb-101) | UPB | Severe Asthma | completed | "NCT06196879 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Upstream Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06196879)) |
| December 16, 2025 | [Zl-1102 1% w/w gel bid for 16 weeks primary completion](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) | ZLAB | Plaque Psoriasis | withdrawn | "NCT06380907 (A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Zai Lab (Hong Kong), Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06380907)) |
| December 16, 2025 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity; Overweight or Obesity | completed | "NCT06973720 (A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-16 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973720)) |
| December 17, 2025 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm)) |
| December 17, 2025 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS | neovascular Age-related Macular Degeneration | completed, positive | "Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive initial data from its Phase 1a single ascending dose (SAD) trial of TH103, a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor, in treatment-na&iuml;ve patients with neovascular age-related macular degeneration (nAMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/d25416dex991.htm)) |
| December 17, 2025 | [Levosimendan trial start](https://sec-api.dev/pdufa/levosimendan) | TENX | PH-HFpEF | completed | "On December 17, 2025, we also announced that we initiated LEVEL-2 (NCT07288398), the second registrational study of TNX-103 in patients with PH-HFpEF." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/34956/000119312526099393/tennx-20251231.htm)) |
| December 17, 2025 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) FDA approval](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, approved | "BLA761433 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20251217, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761433%22)) |
| December 17, 2025 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA | early Alzheimer's disease | completed | "Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer's disease (AD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390025122553/ea027004801ex99-1_tiziana.htm)) |
| December 17, 2025 | [Venglustat (gz402671) primary completion](https://sec-api.dev/pdufa/venglustat-gz402671) | SNY | Fabry Disease | completed | "NCT05206773 (A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05206773)) |
| December 17, 2025 | [Edecesertib primary completion](https://sec-api.dev/pdufa/edecesertib) | GILD | Cutaneous Lupus Erythematosus (CLE) | withdrawn | "NCT05629208 (Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629208)) |
| December 17, 2025 | [Lorundrostat primary completion](https://sec-api.dev/pdufa/lorundrostat) | MLYS | Obstructive Sleep Apnea; Hypertension | completed | "NCT06785454 (A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Mineralys Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06785454)) |
| December 17, 2025 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20251217, review_priority STANDARD; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| December 18, 2025 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | moderate-to-severe plaque psoriasis | completed, positive | "OSAKA Japan AND CAMBRIDGE, Massachusetts, December 18, 2025 - Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506425000174/form6k_121825.htm)) |
| December 18, 2025 | [GLPG3667 topline data readout](https://sec-api.dev/pdufa/glpg3667) | LKFT | dermatomyositis | completed, met | "corticosteroid, OLE: open-label extension, QD: once daily, R: randomization On December 18, 2025, we announced topline results from the GALARISSO study, which are summarized below: The GALARISSO DM study met its primary endpoint, showing that" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1421876/000119312526130447/d54917dex993.htm)) |
| December 18, 2025 | [Vraylar (cariprazine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/cariprazine) | ABBV |  | completed, approved | "NDA204370 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20251218, review_priority PRIORITY; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22)) |
| December 18, 2025 | [IMDELLTRA® (tarlatamab) PDUFA date](https://sec-api.dev/pdufa/tarlatamab) | AMGN | relapsed ES-SCLC | scheduled | "•The U.S. regulatory submission of DeLLphi 304 a global Phase 3 confirmatory study evaluating IMDELLTRA vs. standard of care in subjects with relapsed ES-SCLC after platinum-based first-line chemotherapy was accepted with a PDUFA date of December 18, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| December 19, 2025 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Financial Results for Fiscal Year 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm)) |
| December 19, 2025 | [MYQORZO® (aficamten) FDA approval](https://sec-api.dev/pdufa/aficamten) | CYTK | To treat symptomatic obstructive hypertrophic cardiomyopathy | completed, approved | "Myqorzo \| aficamten \| 12/19/2025 \| To treat symptomatic obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| December 19, 2025 | [Tebipenem NDA/BLA submission](https://sec-api.dev/pdufa/tebipenem) | SPRO | complicated urinary tract infections | completed | "On December 19, 2025, Spero Therapeutics, Inc. (the "Company") announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK"), filed a New Drug Application ("NDA") resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1701108/000119312525325821/d212013d8k.htm)) |
| December 19, 2025 | [IMCIVREE® (setmelanotide) primary completion](https://sec-api.dev/pdufa/setmelanotide) | RYTM | Obesity; Genetic Obesity | completed | "NCT05093634 (EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor Rhythm Pharmaceuticals, Inc.; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05093634)) |
| December 19, 2025 | [LBL-007 primary completion](https://sec-api.dev/pdufa/lbl-007) | ONC | Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer | completed | "NCT05635708 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05635708)) |
| December 19, 2025 | [Carbetocin primary completion](https://sec-api.dev/pdufa/carbetocin) | ACAD | Hyperphagia in Prader-Willi Syndrome | withdrawn | "NCT06420297 (OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor ACADIA Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06420297)) |
| December 19, 2025 | [BOSTON SCIENTIFIC CORP primary completion](https://sec-api.dev/companies/bsx/catalysts) | BSX | In-Stent Restenosis | completed | "NCT06492174 (A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor Boston Scientific Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06492174)) |
| December 19, 2025 | [AZD5004 primary completion](https://sec-api.dev/pdufa/azd5004) | AZN | Diabetes Mellitus, Type 2 | completed | "NCT06579105 (Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06579105)) |
| December 19, 2025 | [Zepbound (tirzepatide) label expansion decision](https://sec-api.dev/pdufa/tirzepatide) | LLY |  | completed, approved | "NDA215866 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20251219, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product MOUNJARO (TIRZEPATIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215866%22)) |
| December 20, 2025 | [IMCIVREE® (setmelanotide) PDUFA date](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | delayed | "-- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm)) |
| December 21, 2025 | [Beaming white primary completion](https://sec-api.dev/pdufa/beaming-white) | CL | Health Adult Subjects | completed | "NCT07225478 (Clinical Study to Evaluate the Tooth Whitening Efficacy of a New NextGen In-office Whitening System): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-21 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225478)) |
| December 22, 2025 | [Boncresa (boncresa) FDA approval](https://sec-api.dev/pdufa/boncresa) | AMRX |  | completed, approved | "Subsequently, on December 22, 2025, we received FDA approval for both products, which will be marketed under the names Boncresa™ and Oziltus™, respectively." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)) |
| December 22, 2025 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "EX-99.1 enGene Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm)) |
| December 22, 2025 | [Mucinex 12hr Cold & Fever Multi-Symptom (dextromethorphan hydrobromide; guaifenesin; naproxen sodium) FDA approval](https://sec-api.dev/pdufa/dextromethorphan-guaifenesin-naproxen) | RBGLY |  | completed, approved | "NDA217338 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20251222, review_priority STANDARD; sponsor_name RECKITT BENCKISER; product MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM (DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217338%22)) |
| December 22, 2025 | [Lorundrostat NDA/BLA submission](https://sec-api.dev/pdufa/lorundrostat) | MLYS | hypertension in combination with other antihypertensive drugs | completed | "We submitted our NDA for lorundrostat to the FDA on December 22, 2025, and we have not yet received regulatory approval from the FDA or from other regulatory jurisdictions." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)) |
| December 22, 2025 | [Cibinqo (abrocitinib) primary completion](https://sec-api.dev/pdufa/abrocitinib) | PFE | Dermatitis, Atopic | completed | "NCT03422822 (Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03422822)) |
| December 22, 2025 | [V114 primary completion](https://sec-api.dev/pdufa/v114) | MRK | Acute Otitis Media (AOM) | completed | "NCT04193215 (V114 and Acute Otitis Media (V114-032/PNEU-ERA)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04193215)) |
| December 22, 2025 | [SARCLISA® (isatuximab) primary completion](https://sec-api.dev/pdufa/isatuximab) | SNY | Relapsed/Refractory Multiple Myeloma | completed | "NCT05704049 (A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05704049)) |
| December 22, 2025 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA218316 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20251222, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218316%22)) |
| December 23, 2025 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | CTOR |  | completed | "Announced promising preliminary results of an investigator-initiated Phase I clinical trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/ea027077501ex99-1_citius.htm)) |
| December 23, 2025 | [Coya Therapeutics, Inc. FDA approval](https://sec-api.dev/companies/coya/catalysts) | COYA | FTD, or the FTD IND Milestone, together with the ALS IND Milestone, the IND Milestones | completed, approved | "On December 23, 2025, we received FDA approval of our IND of COYA 302 in patients with FTD, or the FTD IND Milestone, together with the ALS IND Milestone, the IND Milestones." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm)) |
| December 23, 2025 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal year ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/ea027077501ex99-1_citius.htm)) |
| December 23, 2025 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125413/ea027077601ex99-1_citius.htm)) |
| December 23, 2025 | [Yartemlea (narsoplimab-wuug) FDA approval](https://sec-api.dev/pdufa/narsoplimab-wuug) | OMER | To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy | completed, approved | "Yartemlea \| narsoplimab-wuug \| 12/23/2025 \| To treat hematopoietic stem cell transplant-associated thrombotic microangiopathyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| December 23, 2025 | [XOLREMDI® (mavorixafor) primary completion](https://sec-api.dev/pdufa/mavorixafor) | XFOR | WHIM Syndrome | completed | "NCT03995108 (Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-23 (ACTUAL); Lead Sponsor X4 Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03995108)) |
| December 23, 2025 | [TEPEZZA® (teprotumumab) primary completion](https://sec-api.dev/pdufa/teprotumumab) | AMGN | Thyroid Eye Disease | completed | "NCT06248619 (A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-23 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06248619)) |
| December 23, 2025 | [Tolebrutinib complete response letter (CRL)](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA219624_20251223.pdf%22)) |
| December 24, 2025 | [YARTEMLEA® (narsoplimab) FDA approval](https://sec-api.dev/pdufa/narsoplimab) | OMER | hematopoietic stem cell transplant-associated thrombotic microangiopathy | completed, approved | "On December 24, 2025, Omeros Corporation (the "Company" or "we") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774925038758/omer20251218_8k.htm)) |
| December 24, 2025 | [Cic vaccine co-formulated tniv2 , sarscov-2 rs and matrix-m adjuvant primary completion](https://sec-api.dev/pdufa/cic-vaccine-co-formulated-tniv2-sarscov-2-rs-and-matrix-m-adjuvant) | NVAX | COVID-19 | completed | "NCT06291857 (A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-24 (ACTUAL); Lead Sponsor Novavax." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06291857)) |
| December 25, 2025 | [Yellow fever vaccine (live) primary completion](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever | completed | "NCT07222059 (Phase 3 Single Arm, Open Study on vYF in Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-25 (ACTUAL); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222059)) |
| December 26, 2025 | [YARTEMLEA® (narsoplimab) PDUFA date](https://sec-api.dev/pdufa/narsoplimab) | OMER |  | completed, approved | "Following a comprehensive response to an FDA information request, the Agency extended the PDUFA date to December 26, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm)) |
| December 26, 2025 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | with obstructive hypertrophic cardiomyopathy | completed, approved | "Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm)) |
| December 26, 2025 | [OMEROS CORP PDUFA date](https://sec-api.dev/companies/omer/catalysts) | OMER |  | scheduled | "Following the submission of information in response to an information request from FDA, FDA informed the Company that the PDUFA date will be extended to December 26, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1285819/000110465925070554/tm2516030d4_8k.htm)) |
| December 26, 2025 | [Eliglustat gz385660 primary completion](https://sec-api.dev/pdufa/eliglustat-gz385660) | SNY | Gaucher's Disease Type I; Gaucher's Disease Type III | completed | "NCT03485677 (Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-26 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03485677)) |
| December 28, 2025 | [Tolebrutinib PDUFA date](https://sec-api.dev/pdufa/tolebrutinib) | SNY |  | completed, complete response letter | "On December 15, 2025, Sanofi provided an update on the ongoing review which stated that: (i) FDA was expecting the review to go beyond the previously communicated revised US target action date of December 28, 2025; (ii) further guidance from the FDA was expected by the end of the first quarter of 2026; and (iii) in response to an FDA request, Sanofi had submitted an expanded access protocol for tolebrutinib in nrSPMS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312525332163/d65502dex991.htm)) |
| December 29, 2025 | [INO-3107 NDA/BLA acceptance](https://sec-api.dev/pdufa/ino-3107) | INO | RRP and set the Prescription Drug User Fee Act | completed | "As described in Item 8.01 below, on December 29, 2025, Inovio Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted the Company's Biologic License Application ("BLA") for INO-3107, an investigational immunotherapy for the treatment of recurrent respiratory papillomatosis ("RRP") in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1055726/000119312525332322/d78035d8k.htm)) |
| December 29, 2025 | [Mereo BioPharma Group plc topline data readout](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed, negative | "positive or negative results from, or delays in, testing or clinical trials conducted by us, our collaborators, or our competitors, such as the top-line results from the Phase 3 Orbit and Cosmic studies announced in December 29, 2025;" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1719714/000119312526115226/mreo-20251231.htm)) |
| December 29, 2025 | [Efinopegdutide primary completion](https://sec-api.dev/pdufa/efinopegdutide) | MRK | Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD | completed | "NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05877547)) |
| December 29, 2025 | [Soliris (eculizumab) primary completion](https://sec-api.dev/pdufa/eculizumab) | AZN | Generalized Myasthenia Gravis (gMG); Refractory gMG | completed | "NCT06764160 (Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-29 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764160)) |
| December 29, 2025 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity in Diabetes; Type 2 Diabetes Mellitus (T2DM) | completed | "NCT06897202 (A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-29 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897202)) |
| December 30, 2025 | [NEREUSTM (tradipitant) PDUFA date](https://sec-api.dev/pdufa/tradipitant) | VNDA | motion sickness | completed, approved | "Separately, the ongoing review of the pending, fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track, with a PDUFA target action date of December 30, 2025, positioning tradipitant as potentially the first new pharmacologic treatment for motion sickness in over 40 years." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025055393/vnda8-k1242025exhibit991.htm)) |
| December 30, 2025 | [KETAFREE (ketamine) PDUFA date](https://sec-api.dev/pdufa/ketamine) | NRXP |  | scheduled | "The anticipated PDUFA date for this settlement is prior to December 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1719406/000143774925017252/nrxp20250331c_10q.htm)) |
| December 30, 2025 | [Corcept PDUFA date](https://sec-api.dev/pdufa/corcept) | CORT |  | completed, complete response letter | "FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312525044123/d914293dex991.htm)) |
| December 30, 2025 | [NEREUSTM (tradipitant) NDA/BLA acceptance](https://sec-api.dev/pdufa/tradipitant) | VNDA | motion sickness | scheduled | "•The NDA for tradipitant for the treatment of motion sickness was accepted for filing by the FDA with a PDUFA target action date of December 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm)) |
| December 30, 2025 | [Avt03 complete response letter (CRL)](https://sec-api.dev/pdufa/avt03) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761471_20251230.pdf%22)) |
| December 30, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20251230.pdf%22)) |
| December 30, 2025 | [NEREUSTM (tradipitant) FDA approval](https://sec-api.dev/pdufa/tradipitant) | VNDA | vomiting induced | completed, approved | "On December 30, 2025, Vanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved NEREUSTM (tradipitant) for the prevention of vomiting induced by motion." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda-20251230.htm)) |
| December 30, 2025 | [Lifyorli™ (relacorilant) PDUFA date](https://sec-api.dev/pdufa/relacorilant) | CORT | hypercortisolism | scheduled | ""Our New Drug Application (NDA) for relacorilant in hypercortisolism has a Prescription Drug User Fee Act (PDUFA) date of December 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort110425ex991pressrelease.htm)) |
| December 30, 2025 | [Outlook Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed, complete response letter | ""Company") issued a press release announcing that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_8k.htm)) |
| December 30, 2025 | [Qrx003-2% lotion primary completion](https://sec-api.dev/pdufa/qrx003-2-lotion) | QNRX | Netherton Syndrome | completed | "NCT05521438 (Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05521438)) |
| December 2025 | [68ga-psma-11 primary completion](https://sec-api.dev/pdufa/68ga-psma-11) | TLX |  | delayed | "NCT05847348 (68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients): Overall Status UNKNOWN; Phase PHASE3; Primary Completion 2025-12-30 (ESTIMATED); Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05847348)) |
| December 30, 2025 | [Lorundrostat primary completion](https://sec-api.dev/pdufa/lorundrostat) | MLYS | Hypertension | completed | "NCT05968430 (Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Mineralys Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05968430)) |
| December 30, 2025 | [Periguard regimen primary completion](https://sec-api.dev/pdufa/periguard-regimen) | CL | Gingivitis | completed | "NCT07210138 (Clinical Investigation of PerioGard (Test) Regimen): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-30 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07210138)) |
| December 31, 2025 | [Tonix Pharmaceuticals Holding Corp. NDA/BLA acceptance](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "During the year ended December 31, 2025, 13,666; 5,758 (as the Company received FDA acceptance of our NDA filing), and 1 warrants with an exercise price of $1,056, $1,776 and $364,800, respectively, expired." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005730/tnxp-10k_123125.htm)) |
| December 31, 2025 | [Ziihera® (zanidatamab) FDA approval](https://sec-api.dev/pdufa/zanidatamab) | ZYME |  | completed, approved | "Under the Jazz Collaboration Agreement, as of December 31, 2025 we have received (i) a non-refundable $50.0 million upfront payment following receipt of HSR Clearance and delivery of licenses and technology transfer to Jazz, (ii) a further payment of $325.0 million following Jazz's decision to continue the collaboration after readout of the top-line clinical data from HERIZON-BTC-01, in addition to our delivery of other data, analyses and other information, and (iii) a milestone payment of $25.0 million in relation to FDA approval of Ziihera (zanidatamab-hrii) for the treatment of HER2+ BTC." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000015/zyme-20251231.htm)) |
| December 31, 2025 | [Outlook Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | scheduled | "Following a Type A meeting in September 2025, the Company resubmitted the BLA on November 3, 2025, and received a Prescription Drug User Fee Act. ("PDUFA") goal date of December 31, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)) |
| December 31, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | AMR and IgAN, respectively | completed | "During 2025 we made milestone payments to MorphoSys of $35.0 million and $30.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR and IgAN, respectively, which were recognized in acquired in-process research and development, upfront and milestone expense within our consolidated statements of income for the year ended December 31, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm)) |
| December 31, 2025 | [HCW9302 trial start](https://sec-api.dev/pdufa/hcw9302) | HCWB | autoimmune disease | completed | "For the year ended December 31, 2025, the Company was cleared to begin its clinical trial to evaluate HCW9302 in patients with an autoimmune disease in the first quarter and we dosed the first patient in the third quarter." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/hcwb-20251231.htm)) |
| December 31, 2025 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of December 31, 2025, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/cue-20251231.htm)) |
| December 31, 2025 | [KETAFREE (ketamine) PDUFA date](https://sec-api.dev/pdufa/ketamine) | NRXP |  | scheduled | "The anticipated PDUFA date for this NDA is prior to December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/ex_792256.htm)) |
| December 31, 2025 | [Amneal Pharmaceuticals, Inc. complete response letter (CRL)](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed, complete response letter | "(4)For the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-q22026ex991.htm)) |
| December 31, 2025 | [Corcept complete response letter (CRL)](https://sec-api.dev/pdufa/corcept) | CORT | hypertension secondary to hypercortisolism | completed, complete response letter | "On December 31, 2025, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312525338184/d50993d8k.htm)) |
| December 31, 2025 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed | "On December 31, 2025, we reported that we had received a third CRL in which the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm)) |
| December 31, 2025 | [Autolus Therapeutics plc interim data readout](https://sec-api.dev/companies/autl/catalysts) | AUTL |  | scheduled | "The interim results and cash flows are not necessarily indicative of results and cash flows that may be expected for the year ending December 31, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000088/autl-20250930.htm)) |
| December 31, 2025 | [MESOBLAST LTD label expansion decision](https://sec-api.dev/companies/meso/catalysts) | MESO |  | completed, approved | "RYONCIL, first & only FDA approved MSC product ✓Delivered net revenue US$49 million in H1 FY26 ✓Onboarded 49 centers; 64 centers account for ~94% of U.S. pediatric BMTs ✓ Initiating label expansion to adult aGvHD; 3-4x larger market v. pediatric ✓ Prioritize portfolio including inflammatory bowel, neurodegenerative, and respiratory conditions Rexlemestrocel-L second generation platform ✓ Enrollment for CLBP for expected to complete in Mar/Apr ✓ BLA filing next quarter for full approval for RHF in end-stage HfrEF Optimizing manufacturing & logistics to support future growth US$130m cash on hand at Dec 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1345099/000134509926000029/exhibit992h12026results.htm)) |
| December 31, 2025 | [MBX Biosciences, Inc. interim data readout](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | scheduled | "Our historical results for any prior period are not necessarily indicative of our future results, and our interim results are not necessarily indicative of our expected results for the year ended December 31, 2025." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1776111/000119312525217429/424b4_final_prospectus_s.htm)) |
| December 31, 2025 | [AUVELITY (dextromethorphan-bupropion) NDA/BLA acceptance](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | central nervous system | completed | "NEW YORK, December 31, 2025 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of Alzheimer's disease agitation, and has granted the application Priority Review designation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_2.htm)) |
| December 31, 2025 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm)) |
| December 31, 2025 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm)) |
| December 31, 2025 | [Ralinepag primary completion](https://sec-api.dev/pdufa/ralinepag) | UTHR | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension | completed | "NCT03626688 (A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-31 (ACTUAL); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03626688)) |
| December 31, 2025 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Papillary Renal Cell Carcinoma | completed | "NCT05043090 (Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-31 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05043090)) |

Other months: https://sec-api.dev/fda-calendar/2025-11 , https://sec-api.dev/fda-calendar/2026-01. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates December 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-12

```bibtex
@misc{secapidev_fda_calendar_2025_12_20261116,
  title        = {PDUFA dates December 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-12}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_12_20261116","title":"PDUFA dates December 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-12","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
